September 10, 2025 article Open access Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo Vaccine DOI: 10.1016/j.vaccine.2025.127707 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 0 stored of 1 References 16 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial 2020 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 7 patents 173 citations Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial 2021 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access 96 citations Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial 2021 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 2 patents 94 citations Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment 2020 Vaccine article Biochemistry, Genetics and Molecular Biology Virus-based gene therapy research Open access cited by 2 patents 84 citations Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa 2021 PLoS Medicine article Medicine Viral Infections and Outbreaks Research Open access cited by 1 patent 69 citations First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study 2022 PLoS ONE article Medicine Viral Infections and Outbreaks Research Open access 34 citations Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability 2023 Clinical Microbiology and Infection article Medicine Viral Infections and Outbreaks Research Open access 27 citations Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial 2022 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access 27 citations A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus 2020 Journal of Theoretical Biology article Medicine Viral Infections and Outbreaks Research Open access 24 citations Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses 2025 Science Translational Medicine article Medicine Viral Infections and Outbreaks Research 20 citations Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial 2024 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research 19 citations Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone 2023 The Lancet Global Health article Medicine Viral Infections and Outbreaks Research Open access 18 citations Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans 2023 Frontiers in Immunology article Medicine Viral Infections and Outbreaks Research Open access 17 citations Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda 2023 Vaccine article Medicine Viral Infections and Outbreaks Research Open access 11 citations Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola 2023 npj Vaccines article Medicine Viral Infections and Outbreaks Research Open access 10 citations Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo 2023 The Journal of Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access 9 citations 16 results